| KKR |
Report |
Total AUM |
IN-LINE |
pred ~$784B vs. cons $788B |
MEDIUM |
| KKR |
Report |
Adjusted (ANI) EPS |
MISS |
pred ~$1.36 vs. cons $1.43 |
MEDIUM |
| KKR |
Report |
Fee Related Earnings (FRE) per share |
BEAT |
pred ~$1.19 vs. cons $1.15 |
MEDIUM |
| KKR |
Guide |
FY2026 ANI per share outlook (vs. original $7+ target) |
LOWER |
guide ~$6.55 vs. cons $6.80 (FY2026) |
MEDIUM |
| KKR |
Guide |
Global Atlantic / insurance ROE trajectory |
UNCHANGED |
guide ~11.3% vs. cons/target ~12% low-double-digit (FY2026) |
LOW |
| KKR |
Guide |
LTM capital raised / fundraising pace |
UNCHANGED |
guide ~$128B vs. cons $132B LTM (FY2026) |
MEDIUM |
| KKR |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.6% |
— |
MEDIUM |
| KKR |
Return |
5-day cumulative residual |
-2.8% (FADE) |
An ANI/EPS miss driven by slower monetization (Iran-conflict/oil-spike/Fed-hike volatility) reinforces the Q1 walk-back of the $7+ full-year ANI target, prompting sell-side to trim out-year realized performance income estimates even though FRE/fee-earnings growth beats; the stock had already run up ~13% off its June lows into the print on DCC/BX-driven optimism, leaving little cushion for a miss on the most-watched line item, so initial modest downside likely extends over the week as estimate revisions catch down to the more cautious tone on insurance ROE/spread competition and monetization timing. |
MEDIUM |